POS0715 SUSTAINED REMISSION FROM WEEKS 16 TO 52 AND WEEKS 24 TO 52 IN PATIENTS TREATED WITH SARILUMA...
POS0715 SUSTAINED REMISSION FROM WEEKS 16 TO 52 AND WEEKS 24 TO 52 IN PATIENTS TREATED WITH SARILUMAB: POST-HOC ANALYSIS OF SAPHYR TRIAL IN PATIENTS WITH POLYMYALGIA RHEUMATICA
About this item
Full title
Author / Creator
Dasgupta, B. , Praestgaard, A. , Fiore, S. , Ford, K. , Sloane Lazar, J. , Dua, A. and Spiera, R.
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Subjects
More information
Scope and Contents
Contents
BackgroundThe SAPHYR study (NCT03600818) in patients with polymyalgia rheumatica (PMR) who were resistant to glucocorticoid (GC) taper met the primary endpoint with a significantly higher proportion of patients in the sarilumab arm versus the comparator arm achieving sustained remission from weeks 12 to 52 (28.3% vs 10.3%; P=0.0193) [1]. Sarilumab,...
Alternative Titles
Full title
POS0715 SUSTAINED REMISSION FROM WEEKS 16 TO 52 AND WEEKS 24 TO 52 IN PATIENTS TREATED WITH SARILUMAB: POST-HOC ANALYSIS OF SAPHYR TRIAL IN PATIENTS WITH POLYMYALGIA RHEUMATICA
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2824802642
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2824802642
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2023-eular.1989
